| Treasure Gutierrez, MSW | |
|
2650 E Foothill Blvd # 119, Pasadena, CA 91107-3439 | |
| (626) 577-2261 | |
| Not Available |
| Full Name | Treasure Gutierrez |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 2650 E Foothill Blvd # 119, Pasadena, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407330715 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | ASW84238 (California) | Secondary |
| 101YM0800X | Counselor - Mental Health | ASW84238 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Treasure Gutierrez, MSW 500 S Lake St Apt 202, Los Angeles, CA 90057-2769 Ph: (213) 905-2515 | Treasure Gutierrez, MSW 2650 E Foothill Blvd # 119, Pasadena, CA 91107-3439 Ph: (626) 577-2261 |
News Archive
People who survive cancer are less likely to receive necessary care for a wide range of other non-cancer-related medical problems according to a new study published September 13, 2004 in the online edition of CANCER, a peer- reviewed journal of the American Cancer Society.
Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.
Health benefits derived from regular exercise accumulate over the long term, shows a 10-year study in patients with heart failure.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).
People with a genetic predisposition to obesity are at a higher risk of obesity and related chronic diseases from eating fried foods than those with a lower genetic risk, according to a new study from researchers from Harvard School of Public Health, Brigham and Women's Hospital, and Harvard Medical School.
› Verified 3 days ago